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Abstract Ovarian cancer metastasis is associated with an
increase in the urokinase-type plasminogen activator (uPA) and
its receptor uPAR. We present evidence that binding of uPA to
uPAR provokes a mitogenic response in the human ovarian
cancer cell line OV-MZ-6 in which endogenous uPA production
had been significantly reduced by stable uPA ‘antisense’
transfection. High molecular weight (HMW) uPA, independent
of its enzymatic activity, produced an up to 95% increase in cell
number concomitant with 2-fold elevated [3H]thymidine incor-
poration as did the catalytically inactive but uPAR binding
amino-terminal fragment of uPA, ATF. uPA-induced cell
proliferation was significantly decreased by blocking uPA/uPAR
interaction by the monoclonal antibody IIIF10 and by soluble
uPAR. The efficiency of the uPAR binding synthetic peptide
cyclo19;31uPA19ÿ31 to enhance OV-MZ-6 cell growth proved
this molecular domain to be the minimal structural determinant
for uPA mitogenic activity. Dependence of uPA-provoked cell
proliferation on uPAR was further demonstrated in Raji cells
which do not express uPAR and were thus not induced by uPA.
However, upon transfection with full-length uPAR, Raji cells
acquired a significant growth response to HMW uPA and ATF.
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1. Introduction
The serine protease urokinase-type plasminogen activator
(uPA) is synthesized and secreted by normal and malignant
cells and is implicated in a variety of physiological and path-
ophysiological processes including extracellular matrix turn-
over, tumor cell migration, and invasion [1]. The protease
uPA also exerts biological e¡ects characteristic for molecules
with signal transducing properties including chemotaxis, mi-
gration, adhesion, and mitogenesis [2]. Mitogenic activity of
uPA has been observed for several cell types in a highly cell-
type-speci¢c manner with still inconclusive reports on the
structural and molecular requirements [3^11]. Pro-uPA is a
multi-domain proenzyme which encompasses three function-
ally autonomous domains: the amino-terminal growth factor-
like domain (GFD) containing the binding site for the uPA
receptor (uPAR, CD87), the kringle domain, and the serine
protease region. Pro-uPA is converted into proteolytically ac-
tive high molecular weight (HMW) uPA by the action of
certain proteases, e.g. plasmin, HMW kallikrein, cathepsin B
and L, and nerve growth factor-Q [1]. Upon release of the
amino-terminal fragment (ATF = GFD plus kringle domain),
HMW uPA is converted into a still catalytically active form of
uPA, LMW uPA, lacking the uPAR binding site. On cell
surfaces, uPA interacts with a speci¢c glycosylphosphatidyl-
inositol (GPI)-anchored high a⁄nity receptor, uPAR. Upon
binding to uPAR, uPA retains its full catalytic activity thus
converting plasminogen into plasmin [12,13]. The activity of
uPA is controlled by plasminogen activator inhibitors type 1
and type 2 [1].
In recent years several studies have been undertaken to
identify prognostic factors to predict disease-free and overall
survival of patients a¥icted with solid human cancer. A
strong statistically independent prognostic impact has been
attributed to uPA and its inhibitor PAI-1 in a variety of
malignancies [1] including ovarian cancer [14]. The aim of
the present study was to investigate whether uPA stimulates
cell proliferation in ovarian cancer cells and to characterize
the structural elements within the uPA molecule required for
growth factor-like function.
2. Materials and methods
2.1. Materials
Human HMW uPA obtained from Curasan Pharma GmbH (Klei-
nostheim, Germany) was further puri¢ed by FPLC gel using a Hi-
Load 16/60 Superdex 15/75 column (Pharmacia Biotech, Freiburg,
Germany). Inactivation of HMW uPA was achieved with 4U1034
M Pefabloc SC (Pentapharm AG, Basel, Switzerland) or 4U1036 M
H-Glu-Gly-Arg-CH2Cl (Bachem Biochemica, Heidelberg, Germany).
LMW uPA was purchased from Serono, Munich, Germany; human
ATF from American Diagnostica (Greenwich, CT, USA). The uPA-
related peptides cyclo19;31uPA19ÿ31 and cyclo20;30uPA20ÿ31 (V20C;
W30C, C31W) have been described earlier [15]. uPA, PAI-1, uPAR,
and D-dimer concentrations were determined by ELISA kits Imubind
uPA # 894, Imubind PAI-1 # 821, Imubind uPAR # 893, and D-
dimer ELISA, respectively (American Diagnostica). Solid phase uPA
ligand binding assays were performed as published [16]. Recombinant
soluble uPAR (uPAR1ÿ277) expressed in Chinese hamster ovary
(CHO) cells was puri¢ed from cell culture supernatants by uPA ligand
a⁄nity chromatography and its uPA binding activity assessed by £ow
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cyto£uorometry [17]. The monoclonal antibodies (mAb) IIIF10 and
IID7 directed against uPAR were generated as described [18].
[35S]Translabel (methionine/cysteine) and [3H]thymidine were pur-
chased from ICN, Eschwege, Germany; phosphoinositol-speci¢c
phospholipase C (PI-PLC) was from Boehringer Mannheim, Mann-
heim, Germany.
2.2. Establishment of two cell systems to study the mitogenic activity
of uPA
2.2.1. Human ovarian cancer cells. The human ovarian cancer cell
line OV-MZ-6 [19,20] exhibits a broad range of clonal heterogeneity
regarding the expression and protein synthesis of individual cell
clones, including that of uPA. Prior to uPA stimulation we suppressed
endogenous uPA expression by stable uPA ‘antisense’ transfection.
The OV-MZ-6 cell line was subcloned and three OV-MZ-6 cell clones
selected exhibiting uPA, uPAR, and PAI-1 antigen content similar to
the non-clonal wild type cell line. Tumorigenicity of these clones was
con¢rmed in BALB/c nude mice as described [21]. Clone 8 was chosen
and subjected to stable uPA ‘antisense’ transfection using lipofectin. A
uPA cDNA fragment of 647 bp length was cloned in ‘antisense’ ori-
entation into the expression plasmid pRc-RSV (Invitrogen, San Die-
go, CA, USA). Transfections using pRc-RSV with the identical insert
in ‘sense’ orientation or the empty plasmid alone (‘vector’) served as
controls. Several OV-MZ-6 cell clones from each transfection were
isolated upon neomycin selection and tested for expression of uPA,
PAI-1, and uPAR, respectively.
2.2.2. Raji cells. Lymphoblastoid Raji cells were cultivated in
RPMI 1640 medium (Gibco, Eggenstein, Germany), 10% (v/v) fetal
calf serum (FCS), 100 IU/ml penicillin, 100 Wg/ml streptomycin, and
2 mM L-glutamine. Transfection of Raji cells with full-length uPAR
cDNA cloned into pRc-RSV was performed by electroporation (Bio-
Rad Gene Pulser, Munich, Germany) at 250 V and 960 WF. Stably
transfected cell clones were isolated upon selection with neomycin and
puri¢ed to clonality through ¢ve rounds of limited dilutions.
2.3. Treatment of OV-MZ-6 cell with PI-PLC
In order to release GPI-anchored proteins including uPAR from the
tumor cell surface [22], prior to uPA stimulation, OV-MZ-6 cell
monolayers were treated with 5 Wg/ml bacterial PI-PLC in PBS, pH
7.4, for 2 h at 37‡C and washed in PBS thereafter.
2.4. Evaluation of cell proliferation upon uPA stimulation
Cells were cultivated for 24 h in medium containing 1% (v/v) FCS,
a medium in which also uPA stimulation was performed. For the
evaluation of cell proliferation three experimental approaches were
chosen:( a) cell counting, (b) [3H]thymidine incorporation, and (c)
S-phase determinations. (a) Cells were counted in a Neubauer hemo-
cytometer upon Trypan blue exclusion. (b) [3H]Thymidine incorpora-
tion was determined as described earlier [23]. At certain time intervals
after the addition of uPA, OV-MZ-6 cells were pulsed in FCS-free
medium for 1 h with 5 WCi of [3H]thymidine, washed in PBS, detached
with 1% (w/v) EDTA, and precipitated with 10% (v/v) trichloroacetic
acid (TCA) for 30 min. The precipitate was washed in PBS and the
TCA-insoluble fraction dissolved in 1 ml of 0.1 N NaOH, 1% (w/v)
SDS. After liquid scintillation counting counts per minute (cpm) per
cell were evaluated. (c) Determination of S-phase fraction was per-
formed according to Harbeck and coworkers [24].
2.5. In vitro invasion and ¢brin degradation assays
Measurements of in vitro invasion were conducted in a double-¢lter
sandwich assay system as described [25] using metabolically labeled
cells [20]. Fibrin matrix degradation assays were performed with in-
dividual, stable OV-MZ-6 transfectants as described earlier [20].
Crosslinked ¢brin degradation products including D-dimers were
quanti¢ed by ELISA.
3. Results
3.1. E¡ect of uPA ‘antisense’ transfection on uPA content and
invasion of OV-MZ-6 cells
Stable uPA ‘antisense’ transfection reduced uPA secretion
into cell culture supernatants up to 40-fold while uPA ‘sense’
and ‘vector’ OV-MZ-6 transfectants exhibited uPA synthesis
and secretion rates similar to the parental cell line (clone 8)
(Fig. 1). uPAR and PAI-1 levels remained unaltered. Con-
comitant with suppressed uPA synthesis, OV-MZ-6 uPA ‘anti-
sense’ transfectants exhibited a pronounced, up to 30% de-
crease in their invasive capacity and a signi¢cantly reduced
¢brinolytic activity (data not shown). In contrast, uPA ‘sense’
and ‘vector’ OV-MZ-6 transfectants behaved like non-trans-
fected cells.
3.2. E¡ect of uPA on OV-MZ-6 cell proliferation
In principle, a series of di¡erent ovarian carcinoma cell lines
including OV-MZ-6, OV-MZ-13, OV-MZ-19, and OVCAR-3
[19] responded to HMW uPA with increases in cell number.
As test cells we chose the tumorigenic cell line OV-MZ-6 with
signi¢cantly reduced uPA expression due to uPA ‘antisense’
transfection (see Section 2.2). Addition of HMW uPA to OV-
MZ-6 uPA ‘antisense’ transfectants increased cell proliferation
in a concentration-dependent manner. Enhancement of cell
proliferation was maximal (plus 94% þ S.D. 12%) at a uPA
concentration of about 1 nM within 96 h compared to un-
stimulated controls. Higher concentrations of uPA led to a
gradual decrease of the uPA stimulatory e¡ect, an observation
also made in other ligand/receptor systems (Fig. 2). Similar to
increases in OV-MZ-6 cell number, [3H]thymidine incorpora-
tion was about 2-fold induced by 1 nM HMW uPA within
96 h (data not shown). Determination of cell cycle fractions
revealed that in uninduced OV-MZ-6 cells, S-phase fraction
gradually declined within 96 h from 19.8 to 9.5% when cells
were cultured in DMEM containing 1% (v/v) FCS. However,
as soon as HMW uPA was added to cell culture supernatants,
the decline of S-phase fraction was prevented. Thus after 96 h
an about 2.5-fold higher S-phase fraction was found in uPA-
compared to non-stimulated cells. Concomitantly, uPA stim-
ulation led to an up to 15% decrease of the G0/G1 fraction of
the cell cycle. When HMW uPA was inactivated by either
Pefabloc or H-Glu-Gly-Arg-CH2Cl it was still capable of in-
ducing cell proliferation.
3.3. Structural requirements for the mitogenic activity of uPA
In order to de¢ne the structural elements within the uPA
molecule responsible for its cytokine-like activity, OV-MZ-6
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Fig. 1. Quanti¢cation of uPA antigen content in culture superna-
tants of OV-MZ-6 transfectants. OV-MZ-6 cell clones were trans-
fected with uPA ‘antisense’ and uPA ‘sense’ encoding expression
plasmids as described and screened for uPA expression in cell cul-
ture supernatants. Transfections with the plasmid without insert
(‘vector’) and untransfected wild type OV-MZ-6 cells, respectively,
served as controls. uPA antigen content is given as ng/mg protein
of cell lysates.
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uPA ‘antisense’ transfectants were exposed to di¡erent molec-
ular forms of uPA (HMW uPA, LMW uPA, ATF) in equi-
molar concentrations. Exposure of OV-MZ-6 cells to ATF
(Fig. 3) or the ATF fusion proteins ATF-HSA [26] and
ATF-UTI [27] (data not shown) produced similar increases
in cell number as did HMW uPA (plus 69% þ 9.6). HMW
uPA and ATF also provoked a 2-fold elevated [3H]thymidine
incorporation (data not shown). Catalytically active LMW
uPA devoid of the uPAR binding region did not exhibit mi-
togenic activity (Fig. 3) and did also not alter the rate of
[3H]thymidine incorporation. Thus uPA binding to uPAR
was required for mitogenic activity of uPA. In order to deter-
mine the minimal structural elements for mitogenic activity,
OV-MZ-6 uPA ‘antisense’ transfectants were exposed to the
synthetic uPA-derived cyclic peptide cyclo19;31uPA19ÿ31 en-
compassing the uPAR binding region of uPA. The peptide
cyclo19;31uPA19ÿ31 induced a signi¢cant mitogenic response
in OV-MZ-6 uPA ‘antisense’ transfectants whereas the uPA-
related control peptide cyclo20;30uPA20ÿ31 (V20C; W30C,
C31W), which does not bind to uPAR [15], was not e¡ective
(Fig. 3).
3.4. E¡ect of blocking uPA/uPAR interaction on uPA-induced
cell proliferation
The monoclonal antibody mAb IIIF10 (8 Wg/ml) [18] di-
rected against the uPAR binding region of uPA was added
to OV-M-6 uPA ‘antisense’ transfectants 2 h prior to uPA
stimulation followed by repeated additions of the same
amount of mAb IIIF10 every 24 h. Within 96 h mAb
IIIF10 almost completely abrogated uPA-mediated growth-
promoting activity (Fig. 3). MAb IID7 (directed against do-
main II of uPAR) which does not interfere with uPA binding
was ine¡ective (Fig. 3). The addition of recombinant soluble
uPAR (CHO-uPAR1ÿ277) as a ‘scavenger’ for uPA [17] during
the uPA stimulation period of OV-MZ-6 cells also resulted in
a signi¢cantly suppressed mitogenic cell response (Fig. 3).
3.5. Growth-promoting e¡ect of uPA in Raji cells
In order to prove the dependence of the cell growth-pro-
moting e¡ect of uPA on its interaction with uPAR we inves-
tigated its mitogenic activity in Raji cells which do not express
uPAR. Raji cells were exposed to HMW uPA, LMW uPA, or
ATF, and cells were counted after 96 h. Raji cells did not
respond to either molecular form of uPA with increases in
cell number. However, as soon as Raji cells were stably trans-
fected with an expression plasmid encoding uPAR, signi¢cant
responsiveness of Raji cells to HMW uPA (Fig. 4) was ac-
quired resulting in an approximately 40% increase in cell num-
ber. As seen in human ovarian cancer cells, ATF produced a
similar proliferative response of Raji cells whereas LMW uPA
was not e¡ective (data not shown).
3.6. E¡ect of uPAR shedding by PI-PLC on uPA-mediated
growth stimulation
Treatment of OV-MZ-6 uPA ‘antisense’ transfectants with
PI-PLC, known to release GPI-anchored proteins such as
uPAR from cell surfaces [22], prior to uPA stimulation re-
sulted in a complete loss of uPA-triggered growth responses
(data not shown) accompanied by an up to 7-fold increase of
soluble uPAR in cell culture supernatants. The fact that PI-
PLC treatment in non-stimulated cells resulted in a moder-
ately weaker growth promotion compared to non-stimulated
cell which had not been treated by PI-PLC is possibly due to
an additive but weak growth stimulation of cells by auto-
crinely secreted uPA. Release of uPAR by PI-PLC can thus
lead to a further minimal decline in cell growth even in cells
which had not been stimulated by uPA. We also cannot
rule out that other GPI-anchored receptors might be involved
in growth stimulation of cells and are lost upon PLC treat-
ment.
FEBS 21036 2-11-98
Fig. 3. Structural requirements for the mitogenic e¡ect of uPA. OV-
MZ-6 uPA ‘antisense’ transfectants were treated prior to uPA stim-
ulation as described. HMW uPA, LMW uPA, or ATF were added
in equimolar concentrations (1 nM) in DMEM, 1% FCS (v/v). The
uPA-derived synthetic peptide cyclo19;31uPA19ÿ31 was added at 20
Wg/ml based on solid phase uPA ligand binding assays [17]. The
control peptide cyclo20;30uPA20ÿ31 (V20C; W30C, C31W) which did
not exhibit uPAR binding activity served as control. Blockade of
uPA/uPAR interaction was further achieved by mAb IIIF10. The
mAB IID7 which does not interfere with uPA binding to uPAR
served as control. In addition, soluble uPAR (s-uPAR) was coincu-
bated with HMW uPA at a concentration of 3 Wg/ml. Cell numbers
were evaluated by cell counting within 96 h; the values are given as
increases in cell number in %. Five independent experiments were
performed in duplicate; vertical bars indicate the standard error of
the means.
Fig. 2. Concentration-dependent e¡ect of HMW uPA on OV-MZ-6
cell proliferation. OV-MZ-6 uPA ‘antisense’ transfectants were ex-
posed to increasing concentrations of HMW uPA of 0.2^5 nM in
DMEM, 1% (v/v) FCS and incubated for 96 h. Values are given as
cell number in % setting unstimulated controls at 100%. At least
¢ve independent experiments were performed in duplicate; vertical
bars indicate the standard error of the means.
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4. Discussion
Extensive e¡orts have been undertaken to explore biological
features of uPA triggering intracellular signal transduction,
involved in cell proliferation [3^11], cell adhesion, cell migra-
tion, and chemotaxis [2]. Primary tumor growth and the es-
tablishment of metastases require rapid cell proliferation and
the involvement of growth factors. In recent years a mitogen-
like function has been described for uPA which appears to be
highly cell-type-restricted and cell-type-speci¢c regarding the
requirement of structural elements within the uPA molecule.
In the present investigation we studied for the ¢rst time the
mitogenic activity of uPA in di¡erent human ovarian cancer
cells. The increase in cell number was most pronounced in
tumorigenic OV-MZ-6 uPA ‘antisense’ transfectants with a
maximal stimulatory e¡ect at a uPA concentration of about
1 nM. HMW uPA, ATF as well as ATF fusion proteins
[26,27] exhibited comparable growth factor-like activity. At
higher concentrations of HMW uPA a subsequent decline of
the uPA-mediated growth induction was noticed, a phenom-
enon which was also observed in other ligand/receptor systems
and is discussed to be due to receptor desensitization.
In osteosarcoma cells proliferative responses to both HMW
uPA and ATF had been demonstrated before, however, de-
pending on an unaltered glycosylation pattern of uPA. Non-
glycosylated recombinant HMW uPA expressed in Escherichia
coli did not produce a proliferative cell response [7]. More-
over, a special post-translational modi¢cation, a single fuco-
sylation site at threonine-18 of uPA, seemed to be required
[28]. In human ovarian carcinoma cells, however, we showed
that glycosylation was not required for stimulation of cell
proliferation since addition of recombinant ATF, which is
non-glycosylated due to its production in E. coli, was also
e¡ective. In contrast to our ¢ndings, ATF did not induce
cell proliferation in smooth muscle cells [11] and in human
breast cancer cells [10].
In human ovarian cancer cells we proved that the mitogen-
like function of uPA was independent of its enzymatic activity
by pretreating HMW uPA with speci¢c active site blockers.
Inactivation of HMW uPA did not alter its mitogenic activity.
In the human epidermal tumor cell line CCL 20.2 [3,4] and
GUBSB melanoma cells [5], however, it had been demon-
strated before that uPA-induced cell proliferation was only
e¡ective when both aspects, uPAR binding and enzymatic
activity of uPA, were ful¢lled. In the latter study, conse-
quently, cell proliferation could be signi¢cantly reduced by
speci¢c antibodies directed against uPA inhibiting the uPA/
uPAR interaction. Also, monoclonal antibodies directed
against the catalytic center of uPA markedly decreased
[3H]thymidine incorporation [5].
The necessity of uPAR occupation for cytokine-like activity
of uPA in human ovarian cancer cells independent of enzy-
matic activity was veri¢ed by us in another cell system, lym-
phoblastoid Raji cells which do not express uPAR on their
cell surface. Wild type Raji cells did not respond to uPA
stimulation; however, in accordance with our ¢ndings in hu-
man ovarian cancer cells, they did acquire responsiveness to
HMW uPA and ATF upon transfection with an uPAR
cDNA-encoding expression plasmid. These data further sup-
port the notion of a strong dependence of the growth factor-
like activity of uPA on its binding to uPAR which is in line
with the ¢nding that uPAR antibodies blocking uPA/uPAR
interaction [18] abrogated the mitogenic activity of uPA. Re-
duction of growth factor activity of uPA was also achieved by
the addition of soluble recombinant uPAR as ‘scavenger’ for
uPA [17] as well as by shedding uPAR upon PI-PLC treat-
ment of cells [22].
In order to further narrow down the structural elements
within the uPA molecule required for triggering signal trans-
duction, we exposed human ovarian cancer cells to the re-
combinant uPA-derived synthetic peptide cyclo19;31uPA19ÿ31
spanning the uPAR binding region [15]. The peptide cyclo-
19;31uPA19ÿ31 signi¢cantly promoted OV-MZ-6 cell prolifera-
tion thus pointing to the uPAR binding region as the minimal
structural determinant within the uPA molecule.
Current research aims at establishing the molecular basis of
the uPA/uPAR signaling pathway as well as transmembrane
molecules interacting with GPI-anchored uPAR. Integrins
might be candidates in concert with intracellular src protein
tyrosine kinases [29,30] leading to the phosphorylation of cer-
tain proteins [31,32]. In ovarian carcinoma cells a rapid and
transient c-fos gene induction by uPA had been noticed [33].
Moreover, in another human ovarian carcinoma cell line,
IGR-OV1, it had been demonstrated that uPA/uPAR-depend-
ent cell migration is associated with tyrosine kinase activation
[34].
In conclusion, our data suggest that uPA might constitute
an autocrine uPAR-mediated growth-promoting stimulus on
cell surfaces thereby contributing to the rapid growth charac-
teristics of malignant cells. Indeed, aggressively growing tu-
mor cells very often produce signi¢cantly elevated levels of
uPA compared to less aggressive or normal cells [1]. Thus
targeting uPA might be e¡ective not only to reduce tumor
cell invasion but also to provoke an anti-proliferative e¡ect
within cancer therapy.
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Fig. 4. Mitogenic e¡ect of uPA on wild type and uPAR-transfected
Raji cells. Lymphoblastoid Raji cells devoid of detectable uPAR ex-
pression levels were stably transfected with an expression plasmid
encoding uPAR and exposed to 1 nM of HMW uPA (b). HMW
uPA stimulation was also performed with wild type Raji cells (R)
and Raji cells which had been transfected with the empty expression
vector only (8). Cell number was evaluated by cell counting after
96 h. Values are given as cell number in % by setting values from
unstimulated controls at 100%. Three independent experiments were
performed; a typical result is shown.
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